Predictive value of tissue factor bearing microparticles in cancer associated thrombosis
- PMID: 20434015
- DOI: 10.1016/S0049-3848(10)70022-0
Predictive value of tissue factor bearing microparticles in cancer associated thrombosis
Abstract
Venous thromboembolic events (VTE) are a common complication of cancer and its therapy. Prognostic models and biomarkers are currently under investigation as a means to identify cancer patients who are at greatest risk for developing thromboembolic complications and thus are most likely to benefit from primary thromboprophylaxis. Elevations in circulating tissue factor bearing microparticles are associated with thrombosis in cancer patients. We initiated the MicroTEC study which is a randomized, multi-center trial to evaluate the benefit of low molecular weight heparin to prevent VTE in high risk cancer patients. This review details the evidence for tissue factor bearing microparticles in the malignant state and its association with thromboembolic phenomena.
Similar articles
-
Unconventional approaches to the prevention of cancer associated thrombosis.Thromb Res. 2014 May;133 Suppl 2:S44-8. doi: 10.1016/S0049-3848(14)50008-4. Thromb Res. 2014. PMID: 24862145 Review.
-
Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study).Br J Haematol. 2013 Feb;160(4):530-7. doi: 10.1111/bjh.12163. Epub 2012 Dec 13. Br J Haematol. 2013. PMID: 23240761 Free PMC article. Clinical Trial.
-
Systemic treatments for the prevention of venous thrombo-embolic events in paediatric cancer patients with tunnelled central venous catheters.Cochrane Database Syst Rev. 2013 Sep 11;(9):CD009160. doi: 10.1002/14651858.CD009160.pub2. Cochrane Database Syst Rev. 2013. PMID: 24026801 Review.
-
Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy.Clin Cancer Res. 2009 Nov 15;15(22):6830-40. doi: 10.1158/1078-0432.CCR-09-0371. Epub 2009 Oct 27. Clin Cancer Res. 2009. PMID: 19861441 Free PMC article.
-
Treatment of venous thromboembolism in cancer patients.Semin Thromb Hemost. 2007 Oct;33(7):707-11. doi: 10.1055/s-2007-991539. Semin Thromb Hemost. 2007. PMID: 18000799 Review.
Cited by
-
Markers of inflammation and coagulation may be modulated by enteral feeding strategy.JPEN J Parenter Enteral Nutr. 2012 Nov;36(6):732-40. doi: 10.1177/0148607111433054. Epub 2012 Feb 7. JPEN J Parenter Enteral Nutr. 2012. PMID: 22318965 Free PMC article. Clinical Trial.
-
Microparticles and microRNAs: new players in the complex field of coagulation.Intern Emerg Med. 2013 Jun;8(4):291-6. doi: 10.1007/s11739-011-0705-5. Epub 2011 Oct 28. Intern Emerg Med. 2013. PMID: 22033788 Review.
-
Microparticles as Biomarkers of Blood Coagulation in Cancer.Biomark Cancer. 2015 Oct 1;7:51-6. doi: 10.4137/BIC.S30347. eCollection 2015. Biomark Cancer. 2015. PMID: 26462252 Free PMC article. Review.
-
Phosphatidylethanolamine is externalized at the surface of microparticles.Biochim Biophys Acta. 2012 Dec;1821(12):1501-7. doi: 10.1016/j.bbalip.2012.08.017. Epub 2012 Aug 30. Biochim Biophys Acta. 2012. PMID: 22960380 Free PMC article.
-
Biomolecular markers of cancer-associated thromboembolism.Crit Rev Oncol Hematol. 2013 Oct;88(1):19-29. doi: 10.1016/j.critrevonc.2013.02.008. Epub 2013 Mar 21. Crit Rev Oncol Hematol. 2013. PMID: 23522921 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
